Oncology Deal Spree To Continue For AbbVie – Early Cancer Pipeline Outweighs Other Disease R&D

 
• By Lucie Ellis-Taitt and Lubna Ahmed

Cancer focused and charging forwards, AbbVie makes 2017 the year its pipeline will expand a little more. Scrip looks at the company’s growing oncology portfolio and what is yet to come and speaks to medical affairs head Bianca Wittig about challenges intertwined with oncology R&D.

Scientist conducting a laboratory experiment in a cancer research facility in the United States, 1951.
AbbVie Builds On Abbott's Cancer R&D History • Source: Shutterstock/Everett Historical

More from Anticancer

More from Therapy Areas